{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:02:11Z","timestamp":1791910931406,"version":"4.3.4"},"reference-count":36,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,16]]},"DOI":"10.20945\/2359-3997000000558","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:20:51Z","timestamp":1668687651000},"page":"689-693","source":"Crossref","is-referenced-by-count":29,"title":["Medical management of primary hyperparathyroidism"],"prefix":"10.20945","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-0742","authenticated-orcid":false,"given":"Francisco","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3638-9332","authenticated-orcid":false,"given":"Janiere de Moura","family":"N\u00f3brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-0664","authenticated-orcid":false,"given":"Lucian Batista de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20221117072037_B1","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1038\/nrdp.2016.33","article-title":"Primary hyperparathyroidism","volume":"2","author":"Bilezikian","year":"2016","unstructured":"Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:16033.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"key20221117072037_B2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1590\/S0004-27302013000600002","article-title":"Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism","volume":"57","author":"Bandeira","year":"2013","unstructured":"Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, et al. Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013;57(6):406-24.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"10","key":"key20221117072037_B3","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","unstructured":"Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072037_B4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","article-title":"Normocalcemic primary hyperparathyroidism","volume":"16","author":"Cusano","year":"2013","unstructured":"Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33-9.","journal-title":"J Clin Densitom"},{"issue":"5","key":"key20221117072037_B5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.beem.2018.09.004","article-title":"Primary hyperparathyroidism","volume":"32","author":"Silva","year":"2018","unstructured":"Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(5):593-607.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"key20221117072037_B6","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Silverberg","year":"2014","unstructured":"Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-94.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072037_B7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10116","key":"key20221117072037_B8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","article-title":"Hyperparathyroidism","volume":"391","author":"Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168-78.","journal-title":"Lancet"},{"key":"key20221117072037_B9","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.7039.1","article-title":"Primary Hyperparathyroidism","volume":"5","author":"Bandeira","year":"2016","unstructured":"Bandeira L, Bilezikian J. Primary Hyperparathyroidism. F1000Res. 2016;5:F1000 Faculty Rev-1.","journal-title":"F1000Res"},{"issue":"9","key":"key20221117072037_B10","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2015-2022","article-title":"Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation","volume":"100","author":"Walker","year":"2015","unstructured":"Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, et al. Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation. J Clin Endocrinol Metab. 2015;100(9):3443-51.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 4","key":"key20221117072037_B11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/0004563214564400","article-title":"Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency","volume":"52","author":"Das","year":"2015","unstructured":"Das G, Eligar V, Govindan J, Bondugulapati LN, Okosieme O, Davies S. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency. Ann Clin Biochem. 2015;52(Pt 4):462-9.","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"key20221117072037_B12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/cen.12398","article-title":"Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature","volume":"80","author":"Shah","year":"2014","unstructured":"Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014;80(6):797-803.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20221117072037_B13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4158\/EP10202.OR","article-title":"Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density","volume":"17","author":"Chandran","year":"2011","unstructured":"Chandran M, Hoeck HC, Wong HC, Zhang RF, Dimai HP. Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density. Endocr Pract. 2011;17(2):226-34.","journal-title":"Endocr Pract"},{"issue":"7","key":"key20221117072037_B14","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","unstructured":"Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(7):3319-25.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072037_B15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.surg.2019.04.059","article-title":"Skeletal effects of combined medical and surgical management of primary hyperparathyroidism","volume":"167","author":"Orr","year":"2020","unstructured":"Orr LE, Zhou H, Zhu CY, Haigh PI, Adams AL, Yeh MW. Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2020;167(1):144-8.","journal-title":"Surgery"},{"issue":"7","key":"key20221117072037_B16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","unstructured":"Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract. 2009;15(7):705-13.","journal-title":"Endocr Pract"},{"issue":"2","key":"key20221117072037_B17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","unstructured":"Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(2):581-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221117072037_B18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","unstructured":"Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16(1):113-9.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20221117072037_B19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism","volume":"32","author":"Tournis","year":"2014","unstructured":"Tournis S, Fakidari E, Dontas I, Liakou C, Antoniou J, Galanos A, et al. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J Bone Miner Metab. 2014;32(2):151-8.","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"key20221117072037_B20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","unstructured":"Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M, et al. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. J Am Geriatr Soc. 2018;66(3):518-24.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"key20221117072037_B21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka","year":"2020","unstructured":"Miyaoka D, Imanishi Y, Kato E, Toi N, Nagata Y, Kurajoh M, et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine. 2020;69(3):642-9.","journal-title":"Endocrine"},{"issue":"5","key":"key20221117072037_B22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial","volume":"125","author":"Grey","year":"1996","unstructured":"Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996;125(5):360-8.","journal-title":"Ann Intern Med"},{"issue":"14","key":"key20221117072037_B23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women","volume":"160","author":"Orr-Walker","year":"2000","unstructured":"Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000;160(14):2161-6.","journal-title":"Arch Intern Med"},{"issue":"1","key":"key20221117072037_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","unstructured":"Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1-19.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20221117072037_B25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","unstructured":"Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(3):1174-8.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221117072037_B26","doi-asserted-by":"crossref","first-page":"415719","DOI":"10.1155\/2011\/415719","article-title":"Cinacalcet treatment of primary hyperparathyroidism","volume":"2011","author":"Rothe","year":"2011","unstructured":"Rothe HM, Liangos O, Biggar P, Petermann A, Ketteler M. Cinacalcet treatment of primary hyperparathyroidism. Int J Endocrinol. 2011;2011:415719.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"key20221117072037_B27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(1):135-41.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20221117072037_B28","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","unstructured":"Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94(12):4860-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20221117072037_B29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","unstructured":"Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, et al. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015;172(5):527-35.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"key20221117072037_B30","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(8):2766-72.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20221117072037_B31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","unstructured":"Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine. 2011;39(3):283-7.","journal-title":"Endocrine"},{"issue":"5","key":"key20221117072037_B32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","unstructured":"Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407-417.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"key20221117072037_B33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00774-021-01279-2","article-title":"Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism","volume":"40","author":"Choe","year":"2022","unstructured":"Choe HJ, Koo BK, Yi KH, Kong SH, Kim JH, Shin CS, et al. Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism. J Bone Miner Metab. 2022;40(2):292-300.","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"key20221117072037_B34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1590\/S0482-50042011000200003","article-title":"Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica","volume":"51","author":"Fran\u00e7a","year":"2011","unstructured":"Fran\u00e7a TC, Griz L, Pinho J, Diniz ET, Andrade LD, Lucena CS, et al. Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011;51(2):131-7.","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"key20221117072037_B35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-21-0322","article-title":"Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study","volume":"185","author":"Ryh\u00e4nen","year":"2021","unstructured":"Ryh\u00e4nen EM, Koski AM, L\u00f6yttyniemi E, V\u00e4lim\u00e4ki MJ, Kiviniemi U, Schalin-J\u00e4ntti C. Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study. Eur J Endocrinol. 2021;185(4):515-24.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20221117072037_B36","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","unstructured":"Kuchay MS, Mathew A, Kaur P, Mishra SK. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab. 2021;65(5):669-73.","journal-title":"Arch Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:21:18Z","timestamp":1668687678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/medical-management-of-primary-hyperparathyroidism\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,16]]}},"alternative-id":["10.20945\/2359-3997000000558"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000558","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}